title: [Causes of death among 91 HIV-infected adults in the era of potent antiretroviral therapy].
abstract: OBJECTIVE
  To describe the causes of death occurring during the antiretroviral therapy in Casablanca.
  
  
  METHODS
  Retrospective study of a cohort of HIV positive patients attending the infectious diseases unit of Casablanca receiving antiretroviral therapy. Files of 91 patients who died were analyzed.
  
  
  RESULTS
  Since June 1999, 1243 patients were treated and 91 deaths occurred (7, 3%). The mean age at time of death was 36 years. Forty-six patients were male (50, 5%) and 86 were stage C (94, 5%). At the initiation of treatment, mean CD4 count was 96 cells/mL (1-626) and mean plasma HIV- RNA was 5, 65 log10. They have received antiretroviral therapy for a mean of 9 months (1-48 months). At time of death, 37 patients (52, 8%) had a CD4 count greater than 200 cells/mL and 16 patients (23%) had undetectable plasma viral load. In 57 cases (63%), the death occurred within the first year after start of antiretroviral therapy. The main causes of death were: tuberculosis (35%), cryptosporidiosis (19%), cryptococcosis (13%), cerebral toxoplasmosis (9%), Kaposi sarcoma (6%), non Hodgkin's lymphoma (2%), atypical mycobacteriosis (2%), cerebral lymphoma (1%), aspergillosis (1%), HIV wasting syndrome (1%) and cancer of cervix (1%). Non AIDS related deaths were noticed in three cases (3%) and the immune reconstitution inflammatory syndrome in six cases (7%).
  
  
  CONCLUSIONS
  In Casablanca, the main cause of death among HIV-infected patients is tuberculosis. Collaboration between the national tuberculosis and AIDS programs has been established to improve the prevention, detection, diagnosis and management of HIV/tuberculosis co infection.
authors.affiliation: Faculté de médecine et de pharmacie de Casablanca, service des maladies infectieuses, CHU Ibn Rochd de Casablanca, Morocco.
authors.forename: Mustapha
authors.initials: M
authors.lastname: Sodqi
authors.forename: Latifa
authors.initials: L
authors.lastname: Marih
authors.forename: Ahd Oulad
authors.initials: AO
authors.lastname: Lahsen
authors.forename: Rajae
authors.initials: R
authors.lastname: Bensghir
authors.forename: Abdelfatah
authors.initials: A
authors.lastname: Chakib
authors.forename: Hakima
authors.initials: H
authors.lastname: Himmich
authors.forename: Kamal Marhoum
authors.initials: KM
authors.lastname: El Filali
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000453:epidemiology / Q000401:mortality; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000706:statistics & numerical data; D002423:Cause of Death / Q000639:trends; D015331:Cohort Studies; D015897:Comorbidity; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality*; D015497:HIV-1 / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009018:Morocco / Q000453:epidemiology; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents